In genomewide association studies, polymorphisms in the fat mass and obesity-associated gene (FTO) were strongly associated with an increased risk of obesity ([@B1][@B2]--[@B3]). The FTO is expressed in a number of tissues relevant to metabolic diseases, including adipose tissue and skeletal muscle ([@B1]). Whereas some investigators found that the FTO mRNA level was increased in adipose tissue from obese subjects ([@B4]), others reported a negative correlation between FTO expression and BMI ([@B5]), and a reduction in FTO gene expression was observed in adipose tissue depots from rodent models of obesity ([@B6]). Nevertheless, recent results obtained either in knockout mice ([@B7]) or in mice expressing a mutated form of FTO (FTO^I367F^) ([@B8]) demonstrated that a loss of function of FTO is associated with reduced body weight and fat mass, clearly supporting a role of FTO in fat accumulation.

Some FTO polymorphisms have also been associated with type 2 diabetes ([@B9][@B10][@B11][@B12]--[@B13]), but it could be due to the increased BMI ([@B14]). Although several reports suggested that FTO expression could be regulated by environmental factors, such as fasting and feeding ([@B6],[@B15],[@B16]), which are known to impact on insulin responsiveness, only a very few studies have specifically investigated FTO expression in relation to insulin sensitivity. A recent study reported that the age-dependant decline of FTO expression is associated with peripheral defects of glucose and lipid metabolism in adipose tissue and skeletal muscle ([@B17]). However, to date, little is known regarding the factors and the mechanisms controlling FTO expression, as well as its cellular functions, particularly in human skeletal muscle. Therefore, we investigated FTO gene expression and function in human skeletal muscle and unveiled both in vivo and in vitro a new role of FTO in the pathogenesis of type 2 diabetes.

RESEARCH DESIGN AND METHODS
===========================

All participants gave their written consent after being informed of the nature, purpose, and possible risks of the study. The protocol was approved by the ethical committees of the Hospices Civils de Lyon and performed according to French Legislation (Huriet Law). The healthy volunteers were divided into two groups based on their age. None had impaired glucose tolerance or a familial or personal history of diabetes, obesity, dyslipidemia, or hypertension. One group of 10 volunteers (control 50: four women and six men, age: 55.3 ± 3.5 years, BMI: 23.2 ± 0.5 kg/m^2^, A1C: 5.2 ± 0.2%) was age-matched with 10 nondiabetic obese subjects (three women and seven men, age: 52.0 ± 1.4 years, BMI: 33.3 ± 0.9 kg/m^2^, A1C: 5.5 ± 0.3%) and 10 obese type 2 diabetic patients (five women and five men, age: 56.2 ± 2.4 years, BMI: 32.1 ± 1.0 kg/m^2^, A1C: 10.1 ± 0.7%). An unrelated group of healthy lean subjects (control 25: one woman and four men, age: 25.4 ± 1.3 years, BMI: 21.5 ± 0.6 kg/m^2^, A1C: 5.2 ± 0.3%) served as the control group for type 1 diabetic patients (one woman and four men, age: 28.8 ± 1.5 years, BMI: 24.5 ± 1.3 kg/m^2^, A1C: 9.1 ± 0.4%). Type 1 diabetic patients had no familial antecedent of type 2 diabetes, and they were all treated with daily injections of insulin (45 ± 5 IU/day) ([@B18]). Another group of type 2 diabetic patients (three women and three men, age: 52.6 ± 2.9 years, BMI: 29.5 ± 6.9 kg/m^2^) were treated for 12 weeks with 8 mg per day of rosiglitazone (Avandia, GlaxoSmithKline, France). Patients had type 2 diabetes for at least one year and a mean duration of diagnosed diabetes of 4 ± 2 years, and all were treated with metformin alone for at least 3 months (between 1.5 and 2 g/day). They have never been treated with thiazolidinediones or insulin. Metformin treatment was not stopped during the study. They did not have complications and their disease state was of mild severity, as assessed by a mean A1C level of 7.0 ± 0.3%.

After an overnight fast, all subjects underwent a 3-h euglycemic hyperinsulinemic clamp, as described previously ([@B18],[@B19]). Percutaneous biopsies of the *vastus lateralis* muscle were performed under local anesthesia, as previously described ([@B18]).

Another group of six healthy subjects (six men, age: 21.7 ± 1.5 years, BMI: 22.1 ± 1.4 kg/m^2^, A1C: 5.1 ± 0.2) were submitted to a 3-h hyperglycemic euinsulinemic clamp with infusion of somatostatin to inhibit endogenous insulin release ([@B20]). During this clamp, glycemia roughly doubled (preclamp, 5.1 ± 0.3; postclamp, 9.8 ± 1.2 mmol/l; *P* \< 0.0001) to reach levels classically obtained during postprandial glycemic incursion in diabetic states.

Quantification of mRNAs.
------------------------

Total RNA samples from muscles and cell cultures were purified as previously described ([@B18],[@B20]). mRNA levels were measured by reverse transcription followed by real-time PCR using a Rotor-Gene 6000 (Corbett Research, Mortlake, Australia), as previously described ([@B21],[@B22]). Primers were listed in supplementary Table 1, available in an online appendix at <http://diabetes.diabetesjournals.org/cgi/content/full/db10-0281/DC1>. Values were normalized using hypoxanthine guanine phosphoribosyl transferase (HPRT) or TATA box binding protein mRNA, measured as reference genes, which were similar among subjects or culture conditions.

Western blot.
-------------

Muscle biopsies were lysed in PBS containing 1% NP40, 0.5% sodium desoxycholate, 0.1% SDS, an protease inhibitor cocktail, and myotubes in a buffer containing 200 mmol/l NaF, 20 mmol/l NaH~2~PO~4~, 150 mmol/l NaCl, 50 mmol/l HEPES, 4 mmol/l NaVO~4~, 10 mmol/l EDTA, and 2 mmol/l PMSF, with 1% Triton X, 10% glycerol, and protease inhibitor cocktail. Primary antibodies used were FTO (Abcam, ab65366), total Akt (Cell Signaling, no. 9272), phospho-Akt (Cell Signaling, no. 9271), OXPHOS cocktail (Mitosciences, MS604), with tubulin (Santa Cruz, sc-8035) or actin (Sigma A5060) as a loading control.

Protein carbonylation.
----------------------

Total protein carbonylation was detected, using the Oxidized Protein Detection kit (Chemicon), as previously described ([@B23]).

FTO expression vector and recombinant adenovirus.
-------------------------------------------------

The cDNA sequence encoding full-length human FTO was PCR-amplified from IMAGE clone 100016381 (Geneservice U.K. Ltd.). The amplified PCR product was cloned into the pGEM-T Easy vector (Promega) and fully sequenced. It was then excised by digestion with *Eco*RV/*Not*I and cloned into the pcDNA3 vector (Invitrogen), generating the pcDNA3/FTO plasmid. Recombinant adenoviral genome encoding human FTO was generated by homologous recombination and amplified as described previously ([@B24],[@B25]).

Cell culture.
-------------

HEK293 cells were grown in Dulbecco modified Eagle\'s medium (PAA, Germany) supplemented with 10% FBS. Cells were transfected in 6-well plates for 48 h with 3 μg expression plasmid for the FTO gene or with the empty vector as control, using EXGEN 500 transfecting reagent (Euromedex). C~2~C~12~ myoblasts were grown in Dulbecco modified Eagle\'s medium supplemented with 10% FBS. Reducing the serum to 2% induced differentiation. Primary cultures of human myotubes were initiated from satellite cells of muscle (*vastus lateralis*) obtained from four healthy subjects with normal glucose tolerance and insulin sensitivity (2 men/2 women, age: 47 ± 10 years, BMI: 25 ± 2 kg/m^2^). These cells were differentiated into myotubes as previously described ([@B22],[@B26]). Myotubes were infected for 48 h with recombinant adenovirus expressing green fluorescent protein (GFP) (control) or FTO. Inhibition of FTO expression was performed by RNA interference using small interfering RNA against FTO (Qiagen), using the Hiperfect transfection reagent (Qiagen) for 48 h. A rhodamine-labeled GFP-22 siRNA was used as control.

Lipogenesis.
------------

Postinfected myotubes were cultured for 24 h in a serum-free medium containing 5 mmol/l glucose. The rate of lipogenesis from \[2-^14^C\]acetate (0.75 μCi per flask; Perkin Elmer NEC-553) was then measured in the presence of 1 mmol/l acetate during a 24-h period. Labeled fatty acids were extracted according to the Folch Method ([@B27]) and then quantified by liquid scintillation counting. Data were normalized by protein concentrations.

Reactive oxygen species production.
-----------------------------------

Postinfected human myotubes were treated with BSA (0.1%) or palmitate (750 μmol/l) for 16 h, and reactive oxygen species (ROS) production was detected by the nitroblue tetrazolium assay, as previously reported ([@B23]).

Microarray analysis.
--------------------

The procedure used to obtain microarray data has previously been described ([@B7]). Briefly, total RNA extracted from GFP and FTO overexpressing myotubes from four different healthy subjects was hybridized on oligonucleotide microarrays produced by the French Genopole network (RNG), consisting of 25,342 oligonucleotides of 50-mers printed on glass slides. The signal intensities of the microarray spots were loaded to R (version 2.9.2), background corrected with a offset of 50 ([@B28]), lowess normalized within arrays, quantile normalized between arrays, and log-transformed using the limma package from BioConductor ([@B29]). Only spots with a signal-to-noise ratio for Cy3 and Cy5 above 2 and present on the four slides were selected for statistical analysis. The call for differential expression was done by fitting a linear model to each probe ([@B30]). The dataset is available from the GEO database (GSE22857).

ATP synthesis.
--------------

Mitochondrial ATP synthesis in C~2~C~12~ cells was measured according to the protocol of Vives-Bauza et al. ([@B31]).

Statistical analysis.
---------------------

All data are presented as means ± SEM. Normality was tested, and all variables had a Gaussian distribution. Statistical significance was determined using ANOVA when comparing age-matched groups of subjects (lean, obese, and type 2 diabetic subjects). Student paired *t* test was used when comparing mRNA levels before and after the clamp or rosiglitazone treatment in the same group of subjects. Correlations were analyzed using Spearman rank correlation test. Statistical significance of in vitro results was calculated according to unpaired Student *t* test. The threshold for significance was set at *P* \< 0.05.

RESULTS
=======

Metabolic characteristics of the subjects.
------------------------------------------

The metabolic characteristics of the subjects are presented in [Table 1](#T1){ref-type="table"}. After an overnight fast, insulin, nonesterified fatty acid, and triglyceride plasma concentrations were higher in obese individuals, with or without diabetes, than in lean control subjects. Type 2 diabetic patients also had a higher fasting glycemia. The insulin-stimulated glucose disposal rate was profoundly reduced in both obese and type 2 diabetic patients. The type 1 diabetic patients had fasting hyperglycemia compared with age-matched control subjects and displayed a slight, but nonsignificant, reduction in glucose disposal rate during the clamp, indicating that they were not insulin-resistant in contrast to obese and type 2 diabetic patients.

###### 

Clinical and metabolic characteristics of the subjects

                                                                              Control 50      Obese                                          Type 2 diabetes                                                                   Control 25   Type 1 diabetes
  --------------------------------------------------------------------------- --------------- ---------------------------------------------- --------------------------------------------------------------------------------- ------------ --------------------------------------------
  *n*                                                                         10              10                                             10                                                                                5            5
  Men/women                                                                   6/4             7/3                                            5/5                                                                               4/1          4/1
  Age (years)                                                                 55.3 ± 3.5      52.0 ± 1.4                                     56.2 ± 2.4                                                                        25.4 ± 1.3   28.8 ± 1.5
  BMI (kg/m^2^)                                                               23.2 ± 0.5      33.3 ± 0.9[‡](#TF1-3){ref-type="table-fn"}     32.1 ± 1.0[‡](#TF1-3){ref-type="table-fn"}                                        21.5 ± 0.6   24.5 ± 1.3
  A1C                                                                         5.2 ± 0.2       5.5 ± 0.3                                      10.1 ± 0.7[‡](#TF1-3){ref-type="table-fn"}[\*](#TF1-4){ref-type="table-fn"}       5.2 ± 0.3    9.1 ± 0.4
  Basal                                                                                                                                                                                                                                     
      Glucose (mmol/l)[*^a^*](#TF1-1){ref-type="table-fn"}                    4.8 ± 0.1       5.3 ± 0.1                                      10.5 ± 0.7[‡](#TF1-3){ref-type="table-fn"}                                        4.6 ± 0.2    13.5 ± 0.9[†](#TF1-2){ref-type="table-fn"}
      Insulin (pmol/l)[*^a^*](#TF1-1){ref-type="table-fn"}                    34.5 ± 2.9      55.9 ± 10.7[†](#TF1-2){ref-type="table-fn"}    68.2 ± 6.6[‡](#TF1-3){ref-type="table-fn"}                                        32.3 ± 1.5   nd
      Triglycerides (mmol/l)[*^a^*](#TF1-1){ref-type="table-fn"}              0.8 ± 0.1       1.8 ± 0.2[†](#TF1-2){ref-type="table-fn"}      1.9 ± 0.3[‡](#TF1-3){ref-type="table-fn"}                                         0.4 ± 0.1    0.5 ± 0.02
      Nonesterified fatty acid (μmol/l)[*^a^*](#TF1-1){ref-type="table-fn"}   472.1 ± 46.4    644.5 ± 41.3[†](#TF1-2){ref-type="table-fn"}   619.5 ± 49.1[†](#TF1-2){ref-type="table-fn"}                                      492 ± 48     519 ± 97
      Glucose disposal rate \[mg/(kg·min)\]                                   2.4 ± 0.1       1.8 ± 0.1[†](#TF1-2){ref-type="table-fn"}      2.3 ± 0.3                                                                         nd           nd
      Glucose oxidation rate \[mg/(kg·min)\]                                  1.1 ± 0.1       1.0 ± 0.2                                      1.3 ± 0.2                                                                         1.6 ± 0.3    1.5 ± 0.2
      Lipid oxidation rate \[mg/(kg·min)\]                                    0.8 ± 0.1       0.8 ± 0.1                                      0.6 ± 0.1                                                                         nd           nd
  Clamp study                                                                                                                                                                                                                               
      Glucose (mmol/l)                                                        5.0 ± 0.2       5.2 ± 0.4                                      5.4 ± 0.2                                                                         4.5 ± 0.1    5.6 ± 0.2[†](#TF1-2){ref-type="table-fn"}
      Insulin (pmol/l)                                                        810.0 ± 122.5   835.7 ± 150.4                                  1,184.0 ± 67.9[‡](#TF1-3){ref-type="table-fn"}[\*](#TF1-4){ref-type="table-fn"}   875 ± 48     949 ± 115
      Nonesterified fatty acid (μmol/l)                                       25.7 ± 3.5      77.3 ± 23.8                                    93.7 ± 16.7[†](#TF1-2){ref-type="table-fn"}                                       nd           nd
      Glucose disposal rate \[mg/(kg·min)\]                                   10.6 ± 0.9      3.4 ± 0.5[‡](#TF1-3){ref-type="table-fn"}      3.7 ± 0.5[‡](#TF1-3){ref-type="table-fn"}                                         9 ± 1.4      8.2 ± 1.4
      Glucose oxidation rate \[mg/(kg·min)\]                                  3.2 ± 0.2       2.1 ± 0.1[‡](#TF1-3){ref-type="table-fn"}      2.2 ± 0.1[‡](#TF1-3){ref-type="table-fn"}                                         3.5 ± 0.2    3.4 ± 0.2
      Lipid oxidation rate \[mg/(kg·min)\]                                    0.2 ± 0.1       0.3 ± 0.1                                      0.3 ± 0.1[†](#TF1-2){ref-type="table-fn"}                                         6.9 ± 0.7    5.3 ± 0.8

Data are mean ± SEM. The clamp study refers to an euglycemic hyperinsulinemic clamp as detailed in [research design and methods]{.smallcaps}.

^*a*^Parameters measured after an overnight fast;

†*P* \< 0.05 and

‡*P* \< 0.001 vs. the respective control subjects;

\**P* \< 0.05 when comparing type 2 diabetic with obese subjects; nd, not determined.

Regulation of FTO expression in skeletal muscle.
------------------------------------------------

Type 2 diabetic patients had significantly higher skeletal muscle FTO mRNA levels compared either to age-matched lean control subjects or to obese nondiabetic subjects ([Fig. 1](#F1){ref-type="fig"}*A*). However, there was no difference between lean control subjects and obese nondiabetic subjects ([Fig. 1](#F1){ref-type="fig"}*A*). It should be noted that the FTO mRNA levels in skeletal muscle were positively correlated with A1C (*r* = 0.62, *P* = 0.04) and glycemia (*r* = 0.5, *P* = 0.02) and a tendency was observed with the basal rate of lipid oxidation (*r* = −0.48, *P* = 0.06). However, we did not observe correlation of FTO mRNA levels with glucose disposal during the clamp (*r* = 0.22, *P* = 0.43). In addition, increased FTO expression was also demonstrated at the protein level in muscle from type 2 diabetic patients ([Fig. 1](#F1){ref-type="fig"}*B*). Interestingly, there was no difference in FTO mRNA levels between type 1 diabetic subjects and age-matched control subjects ([Fig. 1](#F1){ref-type="fig"}*A*), suggesting that the upregulation of FTO expression observed in type 2 diabetic subjects was not related to chronic hyperglycemia ([Fig. 1](#F1){ref-type="fig"}*A*).

![Regulation of FTO expression in human skeletal muscle. *A*: Basal FTO mRNA levels were measured by real-time RT-PCR in skeletal muscle of age-matched control, obese, type 2 diabetic patients, and type 1 diabetic subjects. Values are means ± SEM (*n* = 5--10). \**P* \< 0.05 versus age-matched control subjects. The mRNA level of the reference gene HPRT did not differ among groups (3.9 ± 0.5, 2.9 ± 0.1, 3.8 ± 0.5, 3.3 ± 0.3, and 4.2 ± 0.5 amo/μg total RNA, in control 50, obese, type 2 diabetic patients \[T2DM\], control 25, and type 1 diabetic patients \[T1DM\], respectively, not significant \[NS\]). *B*: Representative Western blot illustrating FTO protein levels in skeletal muscle of age-matched control, obese, and type 2 diabetic patients. Data of the histogram are means ± SEM (*n* = 3). \**P* \< 0.05 versus age-matched control subjects. *C* and *D*: FTO mRNA levels were measured by real-time RT-PCR in skeletal muscle of age-matched control and type 2 diabetic patients, before and after a 3-h euglycemic hyperinsulinemic clamp (*C*) or a 3-h hyperglycemic euinsulinemic clamp (*D*). Values are means ± SEM (*n* = 6). *E*: FTO mRNA levels were measured by real-time RT-PCR in skeletal muscle of type 2 diabetic patients, before and after a 12-week rosiglitazone treatment. Values are means ± SEM (*n* = 6). \**P* \< 0.05 versus before treatment. The mRNA level of the reference gene HPRT did not differ before and after rosiglitazone treatment (5 ± 0.6 and 6.6 ± 0.5 amo/μg total RNA, respectively, NS). a.u., arbitrary units.](zdb0011164250001){#F1}

To get more insight into the regulatory mechanisms of FTO expression, we investigated the effect of 3 h of hyperinsulinemia on FTO mRNA levels in muscle from control and type 2 diabetic patients. FTO expression was not modified during the euglycemic hyperinsulinemic clamp, in both groups of subjects ([Fig. 1](#F1){ref-type="fig"}*C*). To further test whether FTO expression could be regulated by hyperglycemia, we investigated samples from healthy subjects, submitted to an acute rise of glycemia, independently from insulin ([@B20]). Once again, we did not observe significant changes in FTO expression in muscle samples taken before and after a 3-h hyperglycemic euinsulinemic clamp ([Fig. 1](#F1){ref-type="fig"}*D*).

Because impaired FTO expression was observed only in tissue from type 2 diabetic patients, we investigated the effects of the insulin-sensitizer rosiglitazone on FTO expression in another group of type 2 diabetic subjects. Rosiglitazone treatment for 12 weeks reduced serum insulin levels and significantly improved glucose utilization and oxidation rates (supplementary Table 2, available in an online appendix). The treatment significantly reduced FTO mRNA levels in skeletal muscle ([Fig. 1](#F1){ref-type="fig"}*E*). There was no correlation between the observed changes in FTO expression and improved insulin sensitivity in this small group of subjects (data not shown).

Effect of FTO overexpression on insulin signaling.
--------------------------------------------------

To determine whether the observed upregulation of FTO in muscle from type 2 diabetic patients could contribute to altered insulin action, we transiently overexpressed FTO in HEK293 cells and investigated the consequences on insulin signaling. A twofold increase of FTO protein was associated with a marked increase of basal protein kinase B (PKB) phosphorylation on both Ser473 and Thr308 residues ([Fig. 2](#F2){ref-type="fig"}). Furthermore, the insulin-stimulated phosphorylation of PKB was inhibited in FTO overexpressing cells ([Fig. 2](#F2){ref-type="fig"}).

![Effect of FTO overexpression on insulin signaling in HEK293 cells. HEK293 were transiently transfected with pcDNA3-FTO or empty pcDNA3 vector (control). Forty-eight h posttransfection, cells were depleted in serum for 3 h and stimulated with insulin (10^−7^ M, 10 min). *A*: Representative Western blots of FTO, pSer473PKB, pThr308PKB, and total PKB. *B*: Histogram illustrates the quantification and normalization of the phosphorylation of PKB in control and FTO-overexpressing cells. Values are means ± SEM (*n* = 3). \**P* \< 0.001 versus control cells, \#*P* \< 0.001 FTO versus GFP. Ins, insulin.](zdb0011164250002){#F2}

To confirm this effect in muscle cells, we constructed adenoviruses for the overexpression of either GFP (control) or FTO in differentiated myotubes. Overexpression of FTO in C~2~C~12~ myotubes (fivefold increase) induced a significant increase of basal PKB phosphorylation ([Fig. 3](#F3){ref-type="fig"}*A*). In addition, the phosphorylation of PDK1, the kinase mediating the phosphorylation of PKB on Thr308, was also increased after FTO overexpression. Next, we investigated the effect of FTO on insulin-stimulated PKB phosphorylation. At a maximal concentration of insulin (10^−7^ M), despite a marked reduction in the amplitude of insulin to phosphorylate PKB (3-fold vs. 11-fold increase in GFP-overexpressing cells), insulin was still able to increase PKB phosphorylation in FTO-overexpressing cells ([Fig. 3](#F3){ref-type="fig"}*B*). In addition, FTO overexpression induced basal phosphorylation of both PKB and p70/85-S6 kinase in human myotubes ([Fig. 3](#F3){ref-type="fig"}*C*), indicating also an activation of some PKB downstream events. Silencing FTO using a specific RNAi ([Fig. 3](#F3){ref-type="fig"}*D*) did not significantly modify basal Ser473 PKB phosphorylation in human myotubes ([Fig. 3](#F3){ref-type="fig"}*E*).

![Adenoviral overexpression of FTO in differentiated myotubes. Human myotubes or C~2~C~12~ cells were infected with recombinant adenovirus encoding human FTO or GFP (control) for 48 h. *A*: Representative Western blots of FTO, pSer473PKB, PKB, pPDK1, PDK1, and tubulin, in GFP- or FTO-overexpressing C~2~C~12~ myotubes. *B*: Representative Western blots of pSer473PKB and PKB total, in GFP- or FTO-overexpressing C~2~C~12~ myotubes (210 \[[@B7]\] ifu/well), under basal conditions or after insulin stimulation. Histogram represents means ± SEM (*n* = 4). \**P* \< 0.05 versus basal situation, ^\#^*P* \< 0.05 FTO versus GFP. *C*: Representative Western blots of FTO, pSer473PKB, PKB, p70/85S6K, and actin in human myotubes overexpressing either GFP or FTO (210 \[[@B7]\] ifu/well). *D* and *E*: Myotubes were transfected with siRNA control or specific for FTO for 48 h. *D*: Validation of FTO silencing in muscle cells. *E*: Representative Western blots of pSer473PKB and PKB in myotubes silencing for FTO (50 nmol/l of siRNA). Histogram illustrates the quantification and normalization of the phosphorylation of PKB in myotubes silenced for FTO. Values are means ± SEM (*n* = 3). ifu, inclusion-forming units.](zdb0011164250003){#F3}

Effect of FTO overexpression on lipogenesis and oxidative stress.
-----------------------------------------------------------------

Increased lipids in muscle from type 2 diabetic patients has been associated with insulin resistance ([@B32]). In agreement with its implication in obesity, a role for FTO in lipid accumulation has been previously hypothesized ([@B7],[@B8]). We therefore investigated the role of FTO on lipid accumulation in human myotubes. FTO overexpression significantly increased the rate of lipogenesis compared with GFP-overexpressing myotubes ([Fig. 4](#F4){ref-type="fig"}*A*). In addition, the expression of key genes involved in this pathway were induced by FTO overexpression ([Fig. 4](#F4){ref-type="fig"}*B*), confirming a role for FTO in the control of lipogenesis.

![Effect of FTO overexpression on de novo lipogenesis. Human myotubes were infected with recombinant adenovirus encoding human FTO genome or GFP (control) for 48 h (210 \[[@B7]\] ifu/well). *A*: De novo lipogenesis was measured with \[2-^14^C\]acetate during 24 h. Values are means ± SEM (*n* = 3). \**P* \< 0.05. *B*: mRNA levels of FAS, ACC1, GPAT, and PPARγ were measured by real-time RT-PCR. Data represent means ± SEM (*n* = 4).\**P* \< 0.05. *C*: Palmitate-induced ROS production either in human myotubes overexpressing either GFP or FTO, or in myotubes silencing for FTO (siRNA, 50 nmol/l). After 48 h of infection/transfection, myotubes were incubated with BSA or palmitate (750 μmol/l) for 16 h, and ROS production was measured using nitro-blue tetrazolium chloride assay. Values represent means ± SEM (*n* = 3).\**P* \< 0.05. FAS, fatty acid synthase; ACC1, acetyl-CoA carboxylase 1; GPAT, glycerol-3 phosphate acyltransferase; PPARγ, peroxisome proliferator--activated receptor γ; a.u., arbitrary units; ifu, inclusion-forming units.](zdb0011164250004){#F4}

Lipids are known to induce the production of ROS in skeletal muscle ([@B23]), and ROS have been implicated in insulin resistance and diabetes ([@B33]). We therefore investigated whether FTO could modify lipid-induced ROS production in human myotubes. As shown in [Fig. 4](#F4){ref-type="fig"}*C*, we did not observe a palmitate-induced ROS production in GFP overexpressing myotubes under our experimental conditions. In contrast, a robust increase of palmitate-induced ROS production was observed in cells overexpressing FTO ([Fig. 4](#F4){ref-type="fig"}*C*). A tendency to increased basal ROS production was also noticeable in response to FTO overexpression (*P* = 0.07). Silencing FTO did not modify palmitate-induced ROS production, whereas it tended to reduce basal ROS production ([Fig. 4](#F4){ref-type="fig"}*C*).

Effect of FTO overexpression on mitochondria function.
------------------------------------------------------

Increases of both lipogenesis and ROS production in myotubes could be related to reduced mitochondria function. This hypothesis is supported by the in vivo negative correlation of FTO expression with lipid oxidation observed in the present study and already reported by others ([@B17]). To test this hypothesis, we first performed a transcriptomic analysis to identify genes regulated by FTO overexpression in human myotubes. Microarrays analysis led to the identification of 1,103 regulated spots (for adjusted *P* value \< 0.05 and fold change \> 1.2 ) coding for 1,080 unique genes (542 upregulated and 538 downregulated genes). Using David (<http://david.abcc.ncifcrf.gov/>) to analyze this set of genes, the Gene Ontology class "mitochondrion" showed significant overrepresentation compared with its representation in the human genome (GO:0005739, adjusted *P* value = 2.13 × 10^−3^). The corresponding genes (*n* = 76) are listed in [Table 2](#T2){ref-type="table"}. Then, we further performed structural and functional analysis of mitochondria. Electronic microscopy analysis of human myotubes overexpressing FTO showed no major structural modification, compared with GFP ([Fig. 5](#F5){ref-type="fig"}*A*). Analysis of protein levels of individual OXPHOS complexes revealed a significant reduction in complex II 30 kDa subunit, whereas the expression of NDUFB8, CIII-core2, and CV subunit alpha (characteristics of complexes I, III, and V, respectively) was not altered in human myotubes ([Fig. 5](#F5){ref-type="fig"}*B*). In addition, PPARγ coactivator 1 (PGC1α) mRNA levels were not significantly modified in myotubes overexpressing FTO compared with GFP (PGC1α/TATA box binding protein \[fold vs. GFP\]: 1.0 ± 0.3 vs. 1.1 ± 0.1, *P* = 0.64, respectively). Lastly, we investigated the repercussion of FTO overexpression on in vitro substrate-mediated ATP synthesis. As shown in [Fig. 5](#F5){ref-type="fig"}*C*, FTO overexpression reduced complex I-mediated ATP synthesis in C~2~C~12~ cells, whereas ATP synthesis mediated by complex II substrates was not significantly modified.

###### 

Mitochondria genes regulated by FTO overexpression in human myotubes

  Symbol     Gene name                                                                    GeneID   Fold change
  ---------- ---------------------------------------------------------------------------- -------- -------------
  ACOT9      Acyl-CoA thioesterase 9                                                      23597    −1.25
  ACSL4      Acyl-CoA synthetase long-chain family member 4                               2182     −1.56
  AK2        Adenylate kinase 2                                                           204      −1.47
  ALDH7A1    Aldehyde dehydrogenase 7 family, member A                                    501      1.2
  ATP5B      ATP synthase, H + transporting, mitochondrial F1 complex, beta polypeptide   506      −1.47
  ATP5I      ATP synthase, H + transporting, mitochondrial F0 complex, subunit E          521      1.35
  ATP5J2     ATP synthase, H + transporting, mitochondrial F0 complex, subunit F2         9551     1.25
  BNIP3      BCL2/adenovirus E1B 19kDa interacting protein 3                              664      1.36
  CABC1      Chaperone, ABC1 activity of bc1 complex homolog (S. pombe)                   56997    −1.32
  CCDC56     Coiled-coil domain containing 56                                             28958    −1.43
  CKB        Creatine kinase, brain                                                       1152     −1.54
  COQ2       Coenzyme Q2 homolog, prenyltransferase                                       27235    1.2
  COX18      COX18 cytochrome c oxidase assembly homolog                                  285521   1.32
  COX5B      Cytochrome c oxidase subunit Vb                                              1329     −1.37
  CTSB       Cathepsin B                                                                  1508     −1.35
  CYB5B      Cytochrome b5 type B(outer mitochondrial membrane)                           80777    1.22
  CYBA       Cytochrome b-245, alpha polypeptide                                          1535     −1.27
  CYC1       Cytochrome c-1                                                               1537     −1.27
  DGUOK      Deoxyguanosine kinase                                                        1716     1.2
  DPYSL2     Dihydropyrimidinase-like 2                                                   1808     1.24
  FAM82A2    Family with sequence similarity 82, member A2                                55177    1.21
  GATM       Glycine amidinotransferase (L-arginine:glycine amidinotransferase)           2628     1.37
  GPX1       Glutathione peroxidase 1                                                     2876     −1.43
  HEBP1      Heme binding protein 1                                                       50865    1.27
  HIBCH      3-hydroxyisobutyryl-Coenzyme A hydrolase                                     26275    −1.41
  HSD17B10   Hydroxysteroid (17-beta) dehydrogenase 10                                    3028     −1.32
  IDH3B      Isocitrate dehydrogenase 3 (NAD+) beta                                       3420     1.3
  IDH3G      Isocitrate dehydrogenase 3 (NAD+) gamma                                      3421     1.2
  ISCA1      Iron-sulfur cluster assembly 1 homolog (S. cerevisiae)                       81689    −1.27
  ISOC2      Isochorismatase domain containing 2                                          79763    −7.69
  KIF1B      Kinesin family member 1B                                                     23095    −1.56
  LACTB      Lactamase, beta                                                              114294   −1.25
  LONP1      Lon peptidase 1, mitochondrial                                               9361     1.23
  MCAT       Malonyl CoA:ACP acyltransferase                                              27349    1.28
  MLYCD      Malonyl-CoA decarboxylase                                                    23417    1.23
  MRPL13     Mitochondrial ribosomal protein L13                                          28998    1.24
  MRPL20     Mitochondrial ribosomal protein L20                                          55052    −1.32
  MRPL27     Mitochondrial ribosomal protein L27                                          51264    1.2
  MRPL30     Mitochondrial ribosomal protein L30                                          51263    1.26
  MRPL44     Mitochondrial ribosomal protein L44                                          65080    1.25
  MRPL47     Mitochondrial ribosomal protein L47                                          57129    1.25
  MRPS22     Mitochondrial ribosomal protein S22                                          56945    1.32
  MT-COI     Cytochrome c oxidase                                                         4512     1.24
  MTIF2      Mitochondrial translational initiation factor 2                              4528     1.35
  NAPG       N-ethylmaleimide-sensitive factor attachment protein, gamma                  8774     1.23
  NDUFA11    NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 11,                      126328   1.22
  NDUFA12    NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 12                       55967    1.2
  NDUFA3     NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3,                       4696     −1.41
  NDUFA6     NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 6,                       4700     1.21
  NDUFC1     NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 1                     4717     −1.25
  NDUFS5     NADH dehydrogenase (ubiquinone) Fe-S protein 5, 15kDa                        4725     −1.35
  PARS2      Prolyl-tRNA synthetase 2, mitochondrial (putative)                           25973    −1.43
  PHB2       Prohibitin 2                                                                 11331    1.2
  PMPCB      Peptidase (mitochondrial processing) beta                                    9512     1.22
  PPIF       Peptidylprolyl isomerase F                                                   10105    1.38
  PRDX4      Peroxiredoxin 4                                                              10549    −1.33
  PTCD3      Pentatricopeptide repeat domain 3                                            55037    1.2
  PTRF       Polymerase I and transcript release factor                                   284119   1.3
  RAB32      RAB32, member RAS oncogene family                                            10981    1.23
  RTN4IP1    Reticulon 4 interacting protein 1                                            84816    1.23
  SARS2      Seryl-tRNA synthetase 2, mitochondrial                                       54938    1.88
  SCP2       Sterol carrier protein 2                                                     6342     −1.25
  SLC27A3    Solute carrier family 27 (fatty acid transporter), member 3                  11000    −1.28
  SOD2       Superoxide dismutase 2, mitochondrial                                        6648     −1.28
  SPNS1      Spinster homolog 1 (Drosophila)                                              83985    1.22
  SUPV3L1    Suppressor of var1, 3-like 1 (S. cerevisiae)                                 6832     1.22
  TACO1      Translational activator of mitochondrially encoded cytochrome c oxidase I    51204    1.36
  TIMM10B    Racture callus 1 homolog (rat)                                               26515    1.24
  TIMM23     Translocase of inner mitochondrial membrane 23 homolog (yeast)               10431    −1.32
  TIMM8A     Translocase of inner mitochondrial membrane 8 homolog A (yeast)              1678     1.28
  TIMM8B     Translocase of inner mitochondrial membrane 8 homolog B (yeast)              26521    1.22
  TIMM9      Translocase of inner mitochondrial membrane 9 homolog (yeast)                26520    1.23
  TMLHE      Trimethyllysine hydroxylase, epsilon                                         55217    1.2
  TOMM34     Translocase of outer mitochondrial membrane 34                               10953    1.32
  UQCR       Ubiquinol-cytochrome c reductase                                             10975    −1.27
  VHL        Von Hippel-Lindau tumor suppressor                                           7428     1.24

![Effect of FTO overexpression on mitochondria structure and function in human myotubes. Human myotubes were infected with recombinant adenovirus encoding human FTO genome or GFP (control) for 48 h (210 \[[@B7]\] ifu/well). *A*: Electronic microscopy analysis of human myotubes overexpressing GFP or FTO. *B*: Analysis of the expression of respiratory chain complexes in human myotubes overexpressing GFP or FTO. It should be noted that complex IV was not detected in our conditions. Histograms represent the means ± SEM (*n* = 4). \**P* \< 0.05. NS, not significant. *C*: Analysis of complex I (pyruvate + malate)- and complex II (succinate + rotenone)-mediated ATP synthesis in GFP- and FTO-overexpressing myotubes. Histograms represent the means ± SEM (*n* = 4). \**P* = 0.02. a.u., arbitrary units; ifu, inclusion-forming units. (A high-quality color representation of this figure is available in the online issue.)](zdb0011164250005){#F5}

Decreased expression of FTO-regulated genes in muscle of type 2 diabetic patients.
----------------------------------------------------------------------------------

To confirm in vivo the relevance of our in vitro observations, we measured some FTO-regulated mitochondria genes in skeletal muscle of control and type 2 diabetic patients. We measured the expression of three FTO-regulated genes, selected in [Table 2](#T2){ref-type="table"} on their implication on oxidative metabolism (ATP5B, UQCR) and oxidative stress (SOD2). As observed in vitro, we found a significant reduction of ATP5B and SOD2 in muscle of type 2 diabetic patients compared with control subjects ([Fig. 6](#F6){ref-type="fig"}*A*), whereas a tendency to reduction was observed for UQCR (*P* = 0.06). In addition, PGC1α expression is significantly reduced in muscle of type 2 diabetic patients ([Fig. 6](#F6){ref-type="fig"}*A*). Lastly, protein carbonylation is induced in muscle of type 2 diabetic patients ([Fig. 6](#F6){ref-type="fig"}*B*), indicating an increase of oxidative stress.

![Reduced OXPHOS and antioxidant genes and increased oxidative stress in skeletal muscle of type 2 diabetic patients. *A*: mRNA levels of ATP5B, UQCR, SOD2, and PGC1α were measured by real-time RT-PCR in skeletal muscle of control and type 2 diabetic patients. Data represent means ± SEM (*n* = 10). \**P* \< 0.05. *B*: Immunoblot showing total protein carbonylation in skeletal muscle of control and type 2 diabetic patients. Histogram represents means ± SEM (*n* = 4).\**P* \< 0.05. ATP5B, ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide; UQCR, ubiquinol-cytochrome c reductase; SOD2, superoxide dismutase 2; a.u., arbitrary units; T2DM, type 2 diabetes.](zdb0011164250006){#F6}

DISCUSSION
==========

While variations of the FTO gene are associated with obesity and type 2 diabetes, the in vivo regulation of FTO and its function are still largely unknown. Here, we demonstrate that FTO expression is increased in skeletal muscle from type 2 diabetic patients and that rosiglitazone treatment partially reversed this defect. In addition, FTO overexpression in cultured myotubes enhanced basal PKB phosphorylation, increased lipogenesis and lipid-induced ROS production, and reduced mitochondria oxidative function. Because in vitro effects of FTO were partially confirmed in muscle of type 2 diabetic patients, we suggest that increased FTO expression in these patients may contribute to reduced mitochondria oxidative capacities, excessive lipid accumulation, and oxidative stress, a cluster of metabolic defects known to be associated with type 2 diabetes.

We report for the first time a significant increase of both FTO mRNA and protein levels in *vastus lateralis* muscle from type 2 diabetic patients, compared either to healthy lean control subjects or to BMI-matched obese nondiabetic individuals. However, we found no correlation between FTO expression and insulin sensitivity as estimated by glucose disposal rate during the hyperinsulinemic clamp. This finding may indicate that FTO induction was related to diabetes per se rather than insulin resistance, a conclusion also supported by the fact that FTO mRNA levels were not altered in muscle of insulin-resistant obese subjects. Concerning the regulation of FTO expression, previous data in mice demonstrated that FTO expression could be affected by environmental factors, such as fasting and feeding ([@B6],[@B15],[@B16]), suggesting a possible regulation by hormones and/or nutrients. However, we did not observe rapid regulation of FTO mRNA by either insulin or glucose during specific clamp studies, suggesting that FTO expression is not acutely regulated by insulin or glucose in human skeletal muscle, as recently reported ([@B17],[@B34]). The unaltered expression of FTO in skeletal muscle from type 1 diabetic patients is in agreement with the absence of a direct regulation of FTO during hyperglycemic clamp. This observation reinforces the concept that increased level of FTO in muscle is a characteristic of type 2 diabetes, independently from obesity and whole-body insulin resistance and also from hyperglycemia. Interestingly, therapy with the antidiabetic agent rosiglitazone produced a significant reduction in the expression of FTO in muscle of type 2 diabetic patients. Unfortunately, up to now, the relationship between insulin sensitivity and loss of FTO function has not been systematically examined in mice or in humans ([@B7],[@B8],[@B35],[@B36]), although it is interesting to point out that invalidation of FTO in mice has been associated with a mild improvement of insulin sensitivity ([@B7]).

Our in vitro overexpression experiments showed that FTO increased the basal phosphorylation of major actors of the insulin signaling cascade, such as PDK1, PKB, and p70/85S6K. In muscle cells, however, FTO did not appear to inhibit the effect of insulin on PKB activation, suggesting that the upstream steps of the IRS1/PI3-kinase pathway are not acutely affected by FTO in muscle cells. However, FTO inhibited insulin-induced PKB phosphorylation in HEK293 cells, supporting the concept that FTO is able to affect, directly or indirectly, the signaling pathways. While the increased phosphorylation of PKB on Thr308 is probably related to induced PDK1 activity, it is more difficult to explain increased Ser473 PKB phosphorylation because several PKB-Ser473 kinases, including the rictor-mTOR complex, are known. Alternatively, one cannot exclude that PKB-specific phosphatases were inhibited in FTO overexpressing cells.

A new interesting finding is that FTO overexpression induced lipid accumulation, oxidative stress, and mitochondrial dysfunction in myotubes. Alterations of these biological processes have clearly been associated with type 2 diabetes ([@B33],[@B37]). Interestingly, expression of multiple components of the mitochondrial respiratory chain were altered by FTO overexpression, including six complex I, two complex III, one complex IV, and three complex V. Whereas no genes of complex II were altered by FTO overexpression in our transcriptomic analysis, we found that FTO induced a significant reduction, at protein level, of the iron sulfur subunit of complex II, indicating that complex II was also controlled by FTO overexpression. We sought to determine whether these changes might be occurring via PGC1α, a transcriptional coactivator that regulates mitochondrial biogenesis and plays a crucial role in the regulation of genes involved in oxidative phosphorylation in muscle ([@B38]). Interestingly, FTO encodes a 2-oxoglutarate-dependent nucleic acid demethylase ([@B4]), and methylation of the promoter of PGC1α was altered in muscle of type 2 diabetic patients ([@B39]). However, we found no modification of PGC1α mRNA levels after FTO overexpression in human myotubes. Nevertheless, PGC1α mRNA levels are barely detectable in myotubes; we cannot exclude that a subtle change of PGC1α expression occurred. Nevertheless, we observed, as previously reported ([@B40][@B41]--[@B42]), a significant reduction of PGC1α expression in muscle of type 2 diabetic patients compared with control subjects, indicating that PGC1α and FTO are regulated in an opposite manner in these patients. In a recent study, a positive correlation between FTO and PGC1α mRNA levels were observed in young and elderly twins ([@B17]). This correlation was obtained with nondiabetic subjects and thus cannot be compared with our study. All together, our data suggest that PGC1α is probably not involved in FTO-induced alterations of mitochondria genes under our experimental conditions. Interestingly, the FTO-induced modifications of mitochondria transcriptome is associated with a reduction of oxidative metabolism, as suggested by the decrease of complex I-mediated ATP synthesis. Coupled with the increase of lipid synthesis, these data suggest that FTO induces a shift from oxidation of lipid toward their accumulation in myotubes. These data are in accordance with a recent study showing a negative association between muscle FTO expression and lipid oxidation in a large cohort of young and old subjects ([@B17]). It was also recently demonstrated that mice with a dominant mutation in the mouse FTO gene (FTO^I367F^) showed increased fatty acid gene expression in skeletal muscle ([@B8]). Although this data could suggest enhanced lipid synthesis, this latter was not measured and no conclusion could be drawn regarding the relationship between FTO and lipid storage in muscle. In contrast, our data clearly indicated that increased expression of FTO in myotubes is associated with enhanced lipogenesis.

Strong similarities exist between FTO function in myotubes and alterations in skeletal muscle of type 2 diabetes. Diabetic muscle was characterized by decreased expression of oxidative phosphorylation genes ([@B41],[@B42]), increased lipid accumulation ([@B37]), and increased oxidative stress ([@B33]). All these metabolic alterations are reproduced by overexpression of FTO in human myotubes. Interestingly, we found a reduction of OXPHOS and antioxidant genes and an increase of protein carbonylation in muscle of type 2 diabetic patients, confirming partially in vitro data. Taken together, these data suggest that the increased FTO in muscle of type 2 diabetic patients may contribute to altered oxidative metabolism and increased oxidative stress, which characterize the muscle of these patients. Additional studies are clearly needed now to more precisely investigate the in vivo repercussions of skeletal muscle FTO expression.

In conclusion, we demonstrate that type 2 diabetes is associated with increased FTO expression, reduced expression of OXPHOS and antioxidant genes, and increased oxidative stress in human skeletal muscle. Overexpression of FTO in myotubes induces basal PKB phosphorylation, increases lipogenesis and oxidative stress, and reduces mitochondria oxidative function. Therefore, we propose that FTO may contribute to the muscle defects that characterize type 2 diabetes.
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